1. Pink Sheet
  2. >>Agency Leadership

US FDA Staff Slams Agency Hiring Policies In Report Ahead Of Public Meeting

 
• By Michael Cipriano

Agency to discuss results of report, as well as pending 2018 pilot project designed to modernize its hiring practices.

FDA entrance sign 2016

The level of frustration that mangers at the US FDA have with the agency’s hiring practices probably can’t be overstated. One individual in the agency’s executive leadership has "no idea" how to evaluate a center's hiring performance, while a hiring manager noted that there is "a profound disconnect of mission" in recruiting and retaining talented staff.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA Rare Disease Innovation Hub’s Goals Align With Trump, Leader Says

 
• By Sue Sutter

The hub’s goals of efficiency, centralization and coordination fit with the Trump Administration’s current focus for the FDA, Amy Comstock Rick, director of strategic coalitions, told the Biopharma Congress.

Trump’s US FDA Takeover Similar To Flat Earth Proponents Running NASA, Woodcock Says

 
• By Sue Sutter

The former principal deputy commissioner said the “decapitation” of senior leadership will make resolving internal disputes more difficult, which will slow application reviews. Woodcock also called the FDA layoffs a slow-moving catastrophe.

US FDA Center Directors Are Political Now

 
• By Michael McCaughan

The forced departure of CBER Director Peter Marks is a milestone event for the agency, as center directors now are likely to be treated as political positions subject to change with each new administration.

All US FDA Product Centers May Merge Under Planned Agency Reorganization

 
• By Sarah Karlin-Smith

Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.

More from Agency Leadership

All US FDA Product Centers May Merge Under Planned Agency Reorganization

 
• By Sarah Karlin-Smith

Product reviews for drugs, biologics, devices, tobacco and foods could be consolidated into one office at the FDA, as part of a restructuring plan circulating that was obtained by Pink Sheet.

Pink Sheet Podcast: Understanding The US FDA Reduction-In-Force And Its Long-Term Impact

 
• By Derrick Gingery, Sarah Karlin-Smith, Sue Sutter, and Nielsen Hobbs

Pink Sheet reporter and editors discuss how the massive layoffs will reshape the FDA and its impact on the drug and biologics industries.

‘Highly Problematic’: Acting FDA Commissioner Paused Planned OK Of Novavax Shot

 
• By Sarah Karlin-Smith

Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.